Neopterin and beta 2-microglobulin as serum markers in a placebo-controlled anti-HIV therapy trial

J Carstens, Lars Stubbe Teglbjærg, F T Black

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

The purpose of this study was to evaluate the use of the biologic immune activation markers neopterin and beta 2-microglobulin in monitoring human immunodeficiency virus (HIV)-positive patients without acquired immunodeficiency syndrome (AIDS) treated with isoprinosine and placebo. Serum samples obtained at the commencement of study and samples obtained after 24 weeks were available from 277 HIV-positive patients in the Scandinavian multicentre isoprinosine trial. After 24 weeks' treatment, the concentrations of beta 2-microglobulin and neopterin had increased both in the isoprinosine group and the placebo group. However, in the isoprinosine group the relative increase within beta 2-microglobulin was significantly smaller. Within neopterin, the increase from baseline level was small and not significantly different from the change in the placebo group. The beta 2-microglobulin data might reflect a suppressive effect of isoprinosine on the HIV-induced activation of the cellular immune system. Because of the minor changes, there is no real evidence of neopterin and beta 2-microglobulin being valuable as surrogate markers in monitoring therapy effects of isoprinosine.

OriginalsprogEngelsk
TidsskriftEuropean journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies
Vol/bind33
Udgave nummer9
Sider (fra-til)559-62
Antal sider4
ISSN0939-4974
StatusUdgivet - sep. 1995

Fingeraftryk

Inosine Pranobex
Neopterin
beta 2-Microglobulin
Viruses
Placebos
HIV
Chemical activation
Virus Activation
Monitoring
Immune system
Multicenter Studies
Immune System
Acquired Immunodeficiency Syndrome
Serum

Citer dette

@article{d6a8e04c61dc4a0bb271904aacda8c88,
title = "Neopterin and beta 2-microglobulin as serum markers in a placebo-controlled anti-HIV therapy trial",
abstract = "The purpose of this study was to evaluate the use of the biologic immune activation markers neopterin and beta 2-microglobulin in monitoring human immunodeficiency virus (HIV)-positive patients without acquired immunodeficiency syndrome (AIDS) treated with isoprinosine and placebo. Serum samples obtained at the commencement of study and samples obtained after 24 weeks were available from 277 HIV-positive patients in the Scandinavian multicentre isoprinosine trial. After 24 weeks' treatment, the concentrations of beta 2-microglobulin and neopterin had increased both in the isoprinosine group and the placebo group. However, in the isoprinosine group the relative increase within beta 2-microglobulin was significantly smaller. Within neopterin, the increase from baseline level was small and not significantly different from the change in the placebo group. The beta 2-microglobulin data might reflect a suppressive effect of isoprinosine on the HIV-induced activation of the cellular immune system. Because of the minor changes, there is no real evidence of neopterin and beta 2-microglobulin being valuable as surrogate markers in monitoring therapy effects of isoprinosine.",
keywords = "Adolescent, Adult, Aged, Antiviral Agents, Biological Markers, Biopterin, CD4-Positive T-Lymphocytes, Double-Blind Method, Female, HIV Seropositivity, Humans, Inosine Pranobex, Lymphocyte Count, Male, Middle Aged, Neopterin, Placebos, Retrospective Studies, beta 2-Microglobulin",
author = "J Carstens and Teglbj{\ae}rg, {Lars Stubbe} and Black, {F T}",
year = "1995",
month = "9",
language = "English",
volume = "33",
pages = "559--62",
journal = "European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies",
issn = "0939-4974",
publisher = "De Gruyter",
number = "9",

}

Neopterin and beta 2-microglobulin as serum markers in a placebo-controlled anti-HIV therapy trial. / Carstens, J; Teglbjærg, Lars Stubbe; Black, F T.

I: European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies, Bind 33, Nr. 9, 09.1995, s. 559-62.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Neopterin and beta 2-microglobulin as serum markers in a placebo-controlled anti-HIV therapy trial

AU - Carstens, J

AU - Teglbjærg, Lars Stubbe

AU - Black, F T

PY - 1995/9

Y1 - 1995/9

N2 - The purpose of this study was to evaluate the use of the biologic immune activation markers neopterin and beta 2-microglobulin in monitoring human immunodeficiency virus (HIV)-positive patients without acquired immunodeficiency syndrome (AIDS) treated with isoprinosine and placebo. Serum samples obtained at the commencement of study and samples obtained after 24 weeks were available from 277 HIV-positive patients in the Scandinavian multicentre isoprinosine trial. After 24 weeks' treatment, the concentrations of beta 2-microglobulin and neopterin had increased both in the isoprinosine group and the placebo group. However, in the isoprinosine group the relative increase within beta 2-microglobulin was significantly smaller. Within neopterin, the increase from baseline level was small and not significantly different from the change in the placebo group. The beta 2-microglobulin data might reflect a suppressive effect of isoprinosine on the HIV-induced activation of the cellular immune system. Because of the minor changes, there is no real evidence of neopterin and beta 2-microglobulin being valuable as surrogate markers in monitoring therapy effects of isoprinosine.

AB - The purpose of this study was to evaluate the use of the biologic immune activation markers neopterin and beta 2-microglobulin in monitoring human immunodeficiency virus (HIV)-positive patients without acquired immunodeficiency syndrome (AIDS) treated with isoprinosine and placebo. Serum samples obtained at the commencement of study and samples obtained after 24 weeks were available from 277 HIV-positive patients in the Scandinavian multicentre isoprinosine trial. After 24 weeks' treatment, the concentrations of beta 2-microglobulin and neopterin had increased both in the isoprinosine group and the placebo group. However, in the isoprinosine group the relative increase within beta 2-microglobulin was significantly smaller. Within neopterin, the increase from baseline level was small and not significantly different from the change in the placebo group. The beta 2-microglobulin data might reflect a suppressive effect of isoprinosine on the HIV-induced activation of the cellular immune system. Because of the minor changes, there is no real evidence of neopterin and beta 2-microglobulin being valuable as surrogate markers in monitoring therapy effects of isoprinosine.

KW - Adolescent

KW - Adult

KW - Aged

KW - Antiviral Agents

KW - Biological Markers

KW - Biopterin

KW - CD4-Positive T-Lymphocytes

KW - Double-Blind Method

KW - Female

KW - HIV Seropositivity

KW - Humans

KW - Inosine Pranobex

KW - Lymphocyte Count

KW - Male

KW - Middle Aged

KW - Neopterin

KW - Placebos

KW - Retrospective Studies

KW - beta 2-Microglobulin

M3 - Journal article

VL - 33

SP - 559

EP - 562

JO - European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies

JF - European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies

SN - 0939-4974

IS - 9

ER -